Indomethacin reduces proteinuria in passive Heymann nephritis in rats  by Zoja, Carla et al.
Kidney international, Vol. 31(1987), pp. 1335—1343
Indomethacin reduces proteinuria in passive Heymann
nephritis in rats
CARLA ZOJA, ARIELA BENIGNI, PIERRE VERROUST, PIERRE RoNco, TULLIO BERTANI,
and GIUSEPPE REMUZZI
Mario Negri Institute for Pharmacological Research, Via Gavazzeni Ii, and Division of Nephrology and Dialysis, Ospedali Riuniti di
Bergamo, Largo Barozzi 1, 24100, Bergamo, italy; and INSERM U64, Hôpital Tenon, 4 rue de Ia Chine, Paris, France
Indomethacin reduces proteinuria in passive Heymann nephritis in
rats. Indomethacin has been used to lower proteinuria in human
glomerular diseases with controversial results. The mechanism of
indomethacin beneficial effects has not been established. A possible
explanation is that indomethacin reduces proteinuria by inhibiting the
synthesis of renal prostaglandins (PGs); however, appropriate studies
to address this issue have never been done. The objectives of the
present study were: a) to investigate whether indomethacin influences
protein excretion in an experimental model of immunologically—medi-
ated glomerular disease; b) to establish if the possible favorable effect of
indomethacin on proteinuria is related to a reduction in glomerular
filtration rate (GFR); c) to establish the possible association between
the antiproteinuric effect of indomethacin and its inhibitory effect on
arachidonic acid (AA) metabolites of renal or extrarenal origin; and d)
to further investigate the relationship between proteinuria and renal
thromboxane (Tx) synthesis previously demonstrated in experimental
models of nephrotoxic nephritis and adriamycin (ADR) nephrosis. To
this purpose we used an experimental immune—complex disease, pas-
sive Heymann nephritis (PHN) which was induced in the rat by a single
intravenous (i.v.) injection of heterologous serum directed against a
brush border component (gp 330 antigen). Indomethacin at a dose of 6
mg/kg intraperitoneally (i.p.) administered for four consecutive days to
PHN animals during the period of heavy proteinuria, effectively re-
duced urinary protein excretion. The reduction in proteinuria does not
appear to be a consequence of a reduction in GFR as documented by
inulin clearance. Glomerular synthesis and urinary excretion of
vasodilatory prostacyclin (PGI2) and PGE2 were decreased or un-
changed in PHN animals in respect to control animals. At variance,
isolated glomeruli from rats with PHN studied 16 days after anti-gp 330
serum injection, when animals were heavily proteinuric, generated
significantly more TxB2, the stable breakdown product of TxA2, than
normal glomeruli. Urinary excretion of TxB2 was also significantly
higher in rats with PHN than in normal rats. Indomethacin reduced the
urinary TxB2 excretion by 74%. The administration of a selective
Tx.synthase inhibitor UK-38,485 at a dose fully inhibiting platelet TxA2
synthesis only partially (around 40%) inhibited urinary excretion of
TxB2 and did not reduce urinary protein excretion. These results may
provide the experimental basis for the clinical observation that indo-
methacin has an antiproteinuric effect in humans.
Indomethacin was widely used between 60's and 70's in the
treatment of proteinuric glomerular diseases, with controversial
results [1—4]. No convincing explanations have been provided
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for the antiproteinuric effect of indomethacin in man. Since
indomethacin's favorable effect on proteinuria was more pro-
nounced in condition of sodium depletion, an inhibitory effect
on renin release was proposed [5]. An alternative explanation
was that the reduction of proteinuria following indomethacin is
a consequence of the reduction in glomerular filtration rate
(GFR) [6]. The theory that indomethacin's favorable effect on
proteinuria depends on its inhibitory effect on the enzyme
cyclooxygenase, with the consequent suppression of eicosanoid
synthesis, has also been proposed [6]. However, measurements
of appropriate biochemical parameters are lacking both in
experimental animals or humans given indomethacin to reduce
proteinuria.
The present work was designed to investigate if indomethacin
influences proteinuria in an experimental model of im-
munologically—mediated glomerular damage. We also wanted to
establish if the possible favorable effect of indomethacin on
protein excretion has to be attributed to a reduction in GFR or
to an inhibition of eicosanoid synthesis of renal or extrarenal
origin.
To this purpose we used an experimental immune—complex
disease, passive Heymann nephritis (PHN). PHN can be in-
duced in rats by injection of heterologous antibodies directed
against antigen(s) present along the brush border (BB) of
proximal tubules of the kidney [7, 8]. Immunofluorescence (IF)
microscopy reveals diffuse, finely granular deposits of IgG and
complement along the outer portion of the glomerular capillary
wall, and electron microscopy (EM) demonstrates deposits of
electron—dense material exclusively in the subepithelial space
[7, 8]. Abnormal proteinuria and glomerular immune complex
deposition are the most common findings of this model [9, 10],
which resembles membranous nephropathy in humans. It was
initially believed that PHN was due to glomerular deposition of
circulating immune complexes constituted by BB antigens and
their respective antibodies [8]. More recently, evidence has
converged to indicate that PHN is due to an in situ formation of
immune complexes between a BB related antigen expressed on
glomerular visceral epithelial cells and its respective circulating
antibody [9, 11—13]. Several studies were devoted to establish
the identity of the antigen(s) involved in the glomerular immune
reaction. Recently, Kerjaschki and Farquhar [14], starting from
a purified BB preparation, have isolated a glycoprotein of
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molecular weight of 330,000 dalton (gp 330) localized in the
coated pits of glomerular epithelial cells.
We have used an antiserum specifically directed against the
gp 330 BB antigen to induce PHN in rats.
Methods
Purification of gp 330 antigen
The gp 330 antigen was prepared according to Ronco et al [15]
by afilnity chromatography from sodium deoxycholate (DOC)-
solubilized BB on Sepharose 4 B (Pharmacia, Velizy, France)
covalently linked to a mixture of three monoclonal antibodies:
Fl/12, F3/28 and F31237. Ten milligrams of BB membrane
vesicles were solubilized by incubation for one hour at room
temperature in 1.25% DOC in 50 mr'i Tris HC1, pH 8.6,
containing 1 mri phenylmethylsullonyl fluoride. The superna-
tant was dialyzed overnight at 4°C against 0.1% DOC in Tris
buffer, ultracentrifuged at 100,000 x g and incubated overnight
with 2 ml of antibody—coupled Sepharose 4 B. After extensive
washing, bound antigen was eluted at alkaline pH according to
Parham [16] and was dialyzed against phosphate buffered
saline.
Preparation of anti-gp 330 antibodies
Rabbits were immunized with 50 jig of gp 330 emulsified in
complete Freund's adjuvant. Four immunizations at three week
intervals were performed. The antisera were tested by indirect
IF. When intravenously (i.v.) injected in rats the serum induced
PHN. The inducing serum was 0.5 ml, containing approxi-
mately 500 jig of anti-gp 330 antibody.
Experimental design
Sprague—Dawley, CD-COBS male rats (Charles River Italia
S.p.A., Calco, Italy) weighing 275 to 300 g at the start of the
experiment were used. Animals were fed a standard rat chow
(Altromin Rieper, Vandoies, Italy) and had free access to tap
water. PHN was induced in 48 non-anesthetized rats by a single
i.v. injection of 0.5 ml of heterologous anti-gp 330 serum
through the tail vein. The following experimental groups were
considered:
Heterologous phase. Eight rats were studied in the heterol-
ogous phase of the disease and sacrificed two days after anti-gp
330 serum injection. At this time protein excretion was mea-
sured and thromboxane B2 (TxB2), the stable breakdown prod-
uct of TxA2, 6-keto-PGF1a, the stable hydrolysis product of
prostacyclin (PGI2) and PGE2 production, were studied in
glomerular preparations and urinary samples.
Autologous phase. Eight rats were studied during the autol-
ogous phase of the disease and sacrificed 16 days after PHN
induction. Twenty—four hour protein excretion was measured at
days 0, 2, 6, 9, 12 and 16 after anti-gp 330 serum injection.
Glomerular production and urinary excretion of TxB2, 6-keto-
PGF1,. and PGE2, serum TxB2 production and serum creatinine
were studied at the end of the experimental period.
Proteinuria improvement. In order to establish whether and
by which mechanisms indomethacin could ameliorate protein-
uria, 12 days after PHN induction eight rats were intraperito-
neally injected with indomethacin (Liometacen, Chiesi
Farmaceutici, S.p.A., Parma, Italy) 3 mg/kg bid for four days.
The animals were sacrificed 16 days after anti-gp 330 serum
injection. Proteinuria and urinary excretion of TxB2, 6-keto-
PGF1a and PGE2 were studied before and after indomethacin
treatment. Serum TxB2 production and serum creatinine were
measured at the end of the experimental period.
Suppression of TxB2 excretion. Sixteen PHN rats were used
to determine whether a selective inhibition of Tx synthesis had
the same favorable effect of indomethacin in reducing protein
excretion and to further investigate a possible relationship
between Tx and proteinuria. Twelve days after PHN induction
eight rats were i.p. injected for four consecutive days with the
Tx synthase inhibitor UK-38,485 at the daily dose of 20 mg/kg
divided in three administrations, and eight rats were i.p. in-
jected with an higher dose of UK-38,485 (40 mg/kg divided in
three administrations for the same period of time) in the attempt
to fully suppress the urinary excretion of TxB2. All the animals
were sacrificed 16 days after the PHN induction. Proteinuria
and urinary excretion of TxB2, 6-keto-PGF,a and PGE2 were
studied before and after UK-38,485 treatment. Serum TxB2
production and serum creatinine were measured at the end of
the experimental period.
Clearance studies. Eight PHN rats were used for renal
clearance studies. Four PHN rats were treated with indometh-
acm (3 mg/kg i.p. bid) from day 12 to day 16 after anti-gp 330
serum injection, and four PHN rats received the solvent in
which indomethacin was dissolved, for the same period of time.
Inulin clearance was performed at day 16 after PHN induction
in all animals.
Controls. Eight normal rats were used as controls. Twenty—
four—hour urine samples were collected in metabolic cages.
Proteinuria was determined by the modified Coomassie blue G
dye—binding assay for proteins [17]. Urine samples for Tx and
PG measurement were immediately frozen after collection and
stored at —20°C until the extraction and the radioimmunossay
(RIA) were performed. Blood samples for determination of
serum TxB2 and serum creatinine were collected by intracardi-
ac puncture from ether anesthetized animals at the end of the
experimental period. Platelet TxB2 production in response to
endogenous thrombin was studied by letting multiple I ml
aliquots of whole blood to clot at 37°C for 60 minutes, as
previously described [18]. The sera were frozen and kept at
—20°C until assayed. Serum creatinine was determined by
alkaline picrate method [19].
Histological studies
Renal tissue specimens were obtained from kidney biopsies.
For light microscopy (LM), fragments of the cortex were fixed
in Dubosq—Brazil fluid (80% alcohol, 150 ml; formol, 60 ml;
acetic acid, 15 ml; picric acid, 1 g) and embedded in paraffin.
Sections of 2 iim were stained with Masson's trichrome, hema-
toxylin and eosin, periodic acid staining (periodic acid—Schifi),
and Wilder's reticulin. For IF, sections of 3 jim of fresh frozen
tissue were cut in a cryostat and were incubated with
fluoresceinated sera raised against rabbit IgG and rat IgG and
C3 (N.L. Cappel Laboratories Inc., West Chester, Pennsylva-
nia, USA). The sections were then washed in phosphate—
buffered saline for 45 minutes at room temperature, embedded
in buffered glycerine (pH 7.2), and examined in a Leitz micro-
scope under ultraviolet light using a Ploem epifluorescence
illuminator system. For EM, small pieces of the cortex were
fixed with phosphate—buffered 2.5% glutaraldehyde (pH 7.2) for
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four hours, then rinsed in 0.2 M cacodylate buffer (pH 7.4).
Subsequently the samples were postfixed in 1% osmium
tetroxide at 4°C for one hour, washed in buffer, and immersed
in 0.5% Veronal uranyl acetate. Samples were then dehydrated
through graded alcohol and embedded in Spurr resin. Ultrathin
sections (60 to 80 nm) were cut on an LKB V ultramicrotome
(LKB Instruments, Milan, Italy) and examined with a Zeiss EM
109 (Carl Zeiss, Oberkochen, West Germany).
Isolation and incubation of glomeruli
Treated and control rats were anesthetized with ether and a
cannula was inserted into the lower aorta. Subsequently, the
aorta was clamped above the renal arteries, the renal veins were
cut, and the kidneys were perfused with 60 to 80 ml of
Krebs—Ringer phosphate buffer (KRB) with the following com-
position: 120.29 mri NaC1, 4.82 mivt KCI, 1.21 mri MgSO4, 2.57
mM CaCl2 and 15.6mM phosphate buffer (pH 7.4). When kidney
surfaces were completely blanched, the kidneys were removed
and immediately immersed in ice cold KRB. All subsequent
preparative steps were performed at 4°C. The renal capsules
were removed and the cortex was separated from the medulla.
The cortical segments of the kidneys from animals of the same
group were pooled and finely minced into 1 to 2 mm fragments.
The glomeruli were separated from residual cortical tissue by
passing the homogenate through different size sieves and press-
ing the preparation through a 106 m sieve to exclude the
tubules, and a 75 m sieve to retain the glomeruli. The sieved
tissue, suspended in KRB pH 7.4, was passed through a
25-gauge needle and centrifuged at 140 x g for 120 seconds. The
supernatant was discarded, the pellet resuspended in the same
buffer solution, passed again through the needle, and centri-
fuged. The purity of isolated glomeruli was determined micro-
scopically by counting the number of glomerular and nonglo-
merular particles suspended in a given volume. The final pellet
consisted of decapsulated glomeruli with less than 2% tubular
contamination. EM of the normal isolated glomeruli showed
well preserved ultrastructure with intact endothelial lining,
basement membranes, and distinct epithelial foot—processes.
The glomeruli of treated and control rats were always prepared
in parallel.
Freshly prepared glomeruli from control and treated rats
were resuspended in I ml of KRB at 37°C in room atmosphere
in a Dubnoff shaking bath (120 cycles/mm). Incubation was
stopped after 60 minutes by centrifugation at 3,000 x g for five
minutes, and the supernatant of each tube was collected and
frozen until Tx measurement. Protein concentration was deter-
mined according to the method of Lowry et al [201 with bovine
serum albumin as a standard. The concentration of glomerular
proteins ranged between 300 and 700 igIml.
Urine extraction
Because urine differs from other biological fluids in that it
contains the most complex mixture of arachidonic acid (AA)
metabolites, in addition to a number of factors that may
possibly interfere with any antigen—antibody reaction, we sub-
mitted urinary samples to extraction and silicic acid chroma-
tography before RIA. Six thousand dpm of 3H-TxB2 (New
England Nuclear Boston, Massachusetts, USA, 113 Ci/mmol)
or 3H-6-keto-PGFIa (New England Nuclear, 130 Cu
mmol) or 3H-PGE2 (New England Nuclear, 180 Ci/mmol) in 1
ml of 50 m phosphate buffer pH 7.4 were added to 3 ml
aliquots of urine to serve as a tracer during extraction and
purification. Urine was acidified to pH 3.5 with formic acid
(99%), and applied to a disposable octadecyl (C18) column
(Sep-pak, Millipore, Mildford, Massachusetts, USA) previ-
ously washed with 10 ml methanol and 10 ml water. The column
was eluted with 10 ml of water, 10 ml of n-hexane and 10 ml of
ethylacetate. The ethylacetate fraction was taken to dryness in
a rotary evaporator at 37°C. Silicic acid (Merck, Darmstadt,
Federal Republic of Germany), 0.5 g, was dissolved in 4 ml
benzene/ethylacetate (60:40) (solvent 1) and added to a small
glass column (6 x 0.7 cm). The column was washed with 4 ml
benzene/ethylacetate/methanol (60:40:20) (solvent 2) and 1.5 ml
of solvent 1. For 6-keto-PGF1 , 4 ml of solvent 2a were used
(benzene/ethylacetate/methanol 60:40:30) instead of solvent 2.
The extracted residue was resuspended in 0.2 ml benzene/eth-
ylacetate/methanol (60:40: 10) (solvent 3) and 0.8 ml solvent 1
was added. The mixture was applied to the column, and PG
fractions were eluted with 4 ml of solvent 1 (fraction I: PGA and
PGB) and 8 ml of solvent 2 for TxB2 and PGE2, or 8 ml solvent
2a for 6-keto-PGF1a (fraction II: PGE and PGF). Fraction II
was collected and taken to dryness at 37°C, redissolved in 3 ml
50 mM phosphate buffer pH 7.4 and an aliquot was analyzed for
radioactivity. The recovery of the radioactive tracers for all the
compounds, which ranged from 60 to 75%, was utilized to
correct the measured endogenous concentrations of TxB2,
6-keto-PGF1a and PGE2.
Radioimmunoassay
Unextracted supernatants of glomerular preparations and
extracted urinary samples were assayed for TxB2, the stable
breakdown product of TxA2, 6-keto-PGF1a, the stable hydroly-
sis product of PGI2, and PGE2. Serum samples were assayed for
TxB2. All the samples were diluted in 50 m phosphate buffer
(pH 7.4) before RIA. Unextracted glomerular supernatants
were diluted 1:6 to 1:10 for TxB2, 1:50 to 1:250 for 6-keto-PGF12
and 1:100 to 1:250 for PGE2. Extracted urinary samples were
diluted 1:6 to 1:40 for TxB2, 1:20 to 1:100 for 6-keto-PGF1a and
1:50 to 1:500 for PGE2. Serum samples were assayed for TxB2
at a final dilution of 1:3000 to 1:10.000. Five thousand dpm of
3H-TxB2, or 3H-6-keto-PGF1a or 3H-PGE2 and amounts of
specific rabbit antibodies sufficient to bind 40% of the tritiated
compounds were incubated 16 to 24 hours at 4°C in a final
volume of 1.5 ml to each assay tube. Anti-TxB2, anti-6-keto-
PGF1,. and anti-PGE2 antibodies were used at a final dilution of
1:250,000, 1:300,000 and 1:50,000, respectively. Anti-PGE2
antiserum was provided by Professor Carlo Patrono, Università
Cattolica del Sacro Cuore, Roma, Italy. Separation of free from
antibody—bound tritiated compounds was obtained by rapid
addition of 10 mg of uncoated charcoal (Norit A). Immediately
before the addition of charcoal, 0.1 ml of human PG-free plasma
was added to each tube in order to prevent the adsorption to
charcoal of antibody—bound PGs. One tenth ml of charcoal
suspension in 0.02 M phosphate buffer pH 7.4 (100 mg/mI) was
then added to each sample, which was shaked by a vortex mixer
and centrifuged for 20 minutes at 2,000 x g at 4°C. Supernatant
solution containing antibody—bound Tx or PGs was decanted
directly into 8 ml of Instagel II (Packard Instrument Co. Inc.,
Downers Grove, Illinois, USA). Radioactivity of samples was
counted in a liquid scintillation counter (LS 1800 model, Beck-
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man, Irvine, California, USA). The smallest concentration that
could be measured with 95% confidence was 2 pg/mI for all the
antisera; consequently the detection limit in glomerular prepa-
rations was 12 pg/mI for TxB2, 100 pg/mI for 6-keto-PGF1a and
200 pg/mI for PGE2; in urinary samples was 12 pg/mi for TxB2,
40 pg/mI for 6-keto-PGF1 and 100 pg/mi for PGE2; in serum
samples was 6 ng/ml for TxB2. Results were expressed as ng/mg
protlhr of TxB2,6-keto-PGF1 and PGE2 for glomerular prepara-
tion, ng/ml of TxB2 for serum and nglday of TxB2, 6-keto-PGF1
and PGE2 for urine. The cross—reactivity at 50% displacement
of other arachidonate metabolites with antisera were as follows:
TxB2 antiserum: 2,3-dinor TxB2, 10.5%; 6-keto-PGF1, 0.004%;
PGE2, 0.008%; PGD2, 0.018%; PGF2a, 0.020%; AA, 0.004%.
6-ketoPGF1, antiserum: TxB2, 0.006%; PGE2, 0.37%; PGD2,
0.09%; PGF2a, 3.0%; AA, 0.0023%; PGE2 antiserum: TxB2,
0.015%; 6-keto-PGF1a, 0.014%; PGD2, 0.11%; PGF2., 1.0%.
Validation of RIA measurements was obtained by several
independent criteria: dilution and recovery studies; comparison
among multiple antisera; characterization of the chromato-
graphic pattern of distribution of the extracted PG and Tx-like
immunoreactivity on thin—layer chromatography; comparison
with gas chromatographic mass spectrometric determinations.
Renal clearance studies
Rats were anesthetized by intraperitoneal injection of
Pentothal (50 mg/kg body wt). Surgical preparation consisted of
tracheostomy, cannulation of femoral artery and vein, and
placement of a large—bore polyethylene tube into the bladder
through a small suprapubic incision. A heated table maintained
body temperature at 37°C. Arterial blood pressure was contin-
uously monitored throughout the experiment directly from the
femoral artery by a polyethylene tube (PE-50), connected to a
pressure transducer and a carrier amplifier (Battaglia Rangoni,
Bologna, Italy). GFR was measured by the clearance of inulin
(E. Merck, Darmstadt, FRG). Five g inulin and 900 mg NaCI
were dissolved in 100 ml distilled water. Two ml of this saline
solution containing 5% inulin were infused in the femoral vein
as a priming load, followed by constant infusion of the same
solution via a syringe pump at 2 mI/hr. A 40 minute equilibration
period was allowed after surgery and initiation of infusion in
order to attain constant plasma levels of inulin. Clearance
periods, 30 minutes each, were performed in triplicate. At the
midpoint of each period 100 p1 blood samples were obtained
from the femoral artery and plasma was separated by centrifu-
gation. Urine samples were collected from the bladder in
preweighed vessels. Plasma and urine inulin was determined
by methods previously described [21] modified for microliter
samples.
Results
Time course of proteinuria and histological findings
After a single i.v. injection of heterologous anti-gp 330 serum,
all treated animals developed the nephritis. Proteinuria started
five to six days after anti-gp 330 serum injection, reached
statistically significant values (P < 0.01) after 12 days when
compared to basal level (219 79 versus 22.08 7.48 mg/day),
and persisted during the following days (Fig. 1).
LM showed no abnormalities in the glomeruli of rats injected
with anti-gp 330 serum during the heterologous phase of the
disease. IF 48 hours after i.v. injection of anti-gp 330 revealed
clear, diffuse granular deposition of rabbit IgG along the
glomerular capillary wall. By EM few electron—dense deposits
were present on the outer aspect of glomerular basement
membrane. In the autologous phase at LM glomeruli showed
only a moderate swelling of visceral epithelial cells. In the
lumens of many distal tubules, eosinophilic proteinaceous casts
were seen. By IF a strong granular deposition of rabbit IgG and
rat IgG and C3 was detected along the glomerular capillary
walls. By EM numerous electron—dense deposits were evident
in the lamina rara externa with some areas of epithelial
foot—process fusion.
Glomerular Tx and PG synthesis in rats with PHN
Statistical analysis
All the results are expressed as the mean so. Data were
analyzed using one way analysis of variance. Significance level
of differences between groups was established using Duncan's
multiple range test or Dunnett's test. Protein excretion and
urinary Tx and PG excretion values in PHN animals before and
after indomethacin or UK-38,485 treatment were analyzed
using paired Student's t-test.
Glomerular TxA2 synthesis was measured as generation of
immunoreactive TxB2 in the supernatant of isolated glomeruli.
Glomerular TxB2 production in eight rats studied two days after
the injection of anti-gp 330 serum, before they developed
proteinuria, was not different from control animals (0.15 0.04
v. 0.21 0.05 ng/mg prot/hr, Fig. 2). In contrast, glomerular
TxB2 production in PHN animals studied in the phase of heavy
proteinuria (16 days after anti-gp 330 injection) was significantly
(P < 0.01) higher (0.47 0.10 ng/mg prot/hr) (Fig. 2). Glomer-
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Fig. 1. Urinary protein excretion per day following anti-gp 330 serum
injection. Values are the mean of 8 animals SD *J.) < 0.01, Dunnett's
test, as compared to basal value.
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Fig. 2. Glomerular production and urinary excretion of TxB2 in rats 2
and 16 days after heterologous anti gp 330 serum injection. Values are
mean SD. *p < 0.05; ** < 0.01, Duncan's multiple range test, as
compared to control group.
ular PGI2 synthesis, measured as 6-keto-PGF1a and PGE2
synthesis were significantly (P < 0.01) reduced in PHN rats
both two and 16 days after anti-gp 330 serum injection as
compared to control value (Table 1).
Urinary excretion of Tx and PGs in rats with PHN
Urinary TxB2 in PHN animals studied two days after
heterologous anti-gp 330 serum injection was not significantly
different from controls (28.85 4.98 v. 24.31 7.43 ng/day,
Fig. 2). In contrast, urinary excretion of TxB2 in rats with PHN
studied 16 days after induction of the disease was significantly
(P <0.05) higher (34.09 8.19 ng/day, Fig. 2).
Urinary excretion of 6-keto-PGF1a and PGE2 was not signif-
icantly modified in rats with PHN studied two and 16 days after
anti-gp 330 serum injection (Table 1).
Treatment of PHN rats with indomethacin or UK-38,485 and
effect on platelet TxA2 synthesis
PHN rats during the period of heavy proteinuria were treated
with either the cyclooxygenase inhibitor indomethacin or the
Tx-synthase inhibitor UK-38,485. Twelve days after anti-gp 330
serum injection, eight rats were given indomethacin 6 mg/kg i.p.
for four days, eight rats received the Tx-synthase inhibitor at
the daily dose of 20 mg/kg i.p. for four days, and eight rats
received the Tx-synthase inhibitor at the daily dose of 40 mg/kg
i.p. for the same period of time. Serum TxB2 production was
22.66 5.42 ng/mI for the indomethacin treated group, 54.50
22.15 ng/ml for the group treated with 20 mg/kg of UK-38,485
and 27.80 6.56 ng/ml for the group treated with 40 mg/kg of
UK-38,485. Both inhibitors were effective in reducing signifi-
cantly (P < 0.01) serum TxB2 production of PHN animals as
compared to both control and untreated PHN rats studied at the
corresponding time (224.93 57.25 and 234.66 58.41 ng/ml,
respectively).
Effect of indomethacin on proteinuria and urinary excretion
of AA metabolites
In PHN rats given indomethacin for four days at a dose of 6
mg/kg i.p. urinary protein excretion was significantly (P <
0.001) reduced (67.52 19.49 after the treatment v. 221 61
mg/day before the treatment, Fig. 3). The reduction of protein-
uria was associated with an inhibition of TxB2 urinary excretion
by 74% (9.57 3.98 after the treatment v. 33.25 5.27 ng/day
before the treatment, P < 0.001, Fig. 4).
Urinary excretion of 6-keto-PGF1, and PGE2 were signifi-
cantly (P <0.01) reduced in PHN rats after indomethacin
treatment (6-keto-PGF1,, 6.81 1.50 after the treatment v.
30.23 8.70 ng/day before the treatment; PGE2, 10.32 5.58
after the treatment v. 28.82 7.70 ng/day before the treatment).
Effect of a selective Tx-synthase inhibitor on proteinuria and
urinary excretion of TxB2
To evaluate whether the favorable effect of indomethacin on
proteinuria, presumably due to the fact that indomethacin in
this model is effective in reducing the renal synthesis of TxA2,
could be also obtained by the use of a selective inhibitor of Tx
synthesis, we treated two groups of eight PHN rats with the Tx
synthase inhibitor UK-38,485 at the doses of 20 and 40 mg/kg
i.p. Proteinuria appeared not to be modified by the Tx-synthase
inhibitor irrespective of the dose employed. Figure 3 shows the
mean values of proteinuria before, 235 50 mg/day (day 12)
and after, 455 152 mg/day (day 16) UK-38,485 treatment at
the dose of 20 mg/kg. The latter values were not different from
those obtained in a comparable group of rats not given the
inhibitor, and studied at the same interval from the anti-gp 330
serum injection (450 129 mg/day). Similar results were
obtained in the group of PHN rats treated with 40 mg/kg of
UK-38,485. Proteinuria was 226 80 mg/day before (day 12)
and 432 149 mg/day alter (day 16) the treatment. After the
administration of 20 mg/kg of UK-38,485 urinary TxB2 excre-
tion was reduced by 43% (19.71 5.14 ng/day in PHN rats after
UK-38,485 treatment v. 34 7.63 ng/day in the same animals
before the treatment, P <0.01; Fig. 4). A comparable effect on
TxB2 urinary excretion rate was found with the higher dose of
UK-38,485 we used. TxB2 excretion was reduced by 44% (19.62
0.5
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3.82 nglday in PHN rats after UK-38,485 treatment v. 34.90
4.27 ng/day in the same animals before the treatment).
Urinary 6-keto-PGF1a and PGE2 excretion in rats with PHN
was not significantly modified by the treatment with UK-38,485
(20 mg/kg). 6-keto-PGF1,, excretion was 53.56 29.35 ng/day in
PHN rats after UK-38,485 treatment versus 34.47 12.83
ng/day in the same animals before the treatment. PGE2 excre-
tion was 45.67 19.77 ng/day after UK-38,485 treatment versus
37.11 8.1 nglday in the same rats before the treatment.
Renal function studies in rats with PHN given UK-38,485 or
indomethacin
In order to establish whether the reduction of urinary protein
excretion observed in PHN rats after indomethacin treatment
could be related to an impairment of renal function, we mea-
sured serum creatinine at the end of the experimental period
(Fig. 5). The mean value of serum creatinine of PHN rats
studied 16 days after anti-gp 330 serum injection was not
different from the control group (0.78 0.23 v. 0.65 0.03
mg/dl). PHN rats treated with 20mg/kg of UK-38,485 showed a
normal serum creatinine value (0.66 0.07 mgldl). Comparable
values have been obtained in PHN animals given 40 mg/kg of
UK-38,485 (0.69 0.08 mg/dl). Figure 5 shows that two out of
eight PHN rats given indomethacin had an increase in serum
creatinine (1.22 and 1.28 mgldl, respectively) at the end of the
four days treatment, whereas in the remaining animals given
indomethacin serum creatinine levels were not different from
controls (0.68 0.06 mg/dl). No differences have been ob-
served in the degree of reduction of proteinuria between the two
animals with renal insufficiency as compared to the six animals
which did not develop renal failure, suggesting that the reduc-
tion of proteinuria in this group of animals is unlikely to be the
consequence of an impaired renal function. Since serum creat-
mine may not be an absolute indicator for GFR we also
measured GFR in two additional groups of four PHN animals
with and without indomethacin using inulin clearance. Values
of GFR of PHN rats treated with indomethacin were not
different from those obtained in untreated PHN rats (0.84
0.20 v. 0.94 0.04 ml/min/l00 g). Once again the treatment with
indomethacin was associated with a significant (P < 0.001)
reduction in proteinuria (55 15 mg/day after the treatment v.
225 39 mg/day before the treatment).
Discussion
The results of the present study show that indomethacin at a
dose of 6 mg/kg i.p. administered to rats with PHN induced by
anti-gp 330 serum effectively reduces urinary protein excretion.
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Table 1. Glomerular production and urinary excretion of prostaglandins in rats with passive
Heymann nephritis (PHN) after anti-gp 330 serum injection
Isolated glomeruli nglmg prot/hr
PHN
6-keto-PGF1,.
Controls 2nd day 16th day Controls 2nd day 16th day
1.15
PGE2 2.50 0.51
Urine ng/day
Values represent the mean SD
a P < 0.01, Duncan's multiple range test, as compared to controls.
*
PHN
600
0.58 0.l3a 0.73 0.l4a 27.24 15.54 31.63 5.32 34.47 12.82
1.40 0.33a 1.66 0.I9 41.21 18.26 39.11 21.20 31.83 8.53
PHN PHN
12th day 16th day
600
**
PHN
12th day
PHN
PHN + UK 38,485
16th day
PHN
12th day
Fig. 3. Effect of indomethacin or UK-38,485 treatment on urinary
protein excretion in rats with PHN. Animals were treated with indo-
methacin (6 mg/kg i.p.) or UK-38,485 (20 mg/kg i.p.) for 4 days starting
from day 12 after anti gp 330 serum injection. Twenty—four hour urines
were collected at day 16. Results are expressed as mean SD. *P <
0.01; ** <0.001, paired Student's t-test, as compared to PHN rats at
day 12.
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FL
PHN PHN + indomethacin
12th day 16th day
Fig. 4. Effect of indomethacin or UK-38,485 treatment on urinary
excretion of TxB2 in rats with PHN. Indomethacin (6 mg/kg i.p.) or
UK-38,485 (20 mg/kg i.p.) were administered for four days starting from
day 12 after anti-gp 330 serum injection. Twenty—four hour urines were
collected at day 16. Results are expressed as mean SD. *P < 0.01;
<0.001, paired Student's t-test, as compared to PHN rats at day 12.
The reduction in proteinuria does not appear to be a conse-
quence of a reduction in GFR since both serum creatinine and
inulin clearance were not modified in PHN animals given
indomethacin or the vehicle. The antiproteinuric effect of
indomethacin in our study is consistent with the results ob-
tained by Kirschenbaum, Liebross and Serros [22] who studied
the effect of indomethacin on proteinuria in another model of
Heymann nephritis induced in rats by the administration of
autologous tubular FxlA antigen. These authors considered the
possibility that indomethacin induces structural changes in
podocytes [231, re-establishing the integrity of glomerular filtra-
tion barrier. However, they were unable to find changes in the
structure of glomerular visceral epithelial cells after examining
indomethacin or vehicle treated animals by electron micros-
copy. To clarify if the favorable effect of indomethacin on
proteinuria could be attributed to the drug's inhibitory effect on
the PG-forming enzyme cyclooxygenase, Kirschenbaum et al
[22] studied the urinary excretion of PGE in animals with
Heymann nephritis treated with indomethacin. They found that
indomethacin significantly inhibited urinary PGE excretion, but
a simple relationship between this phenomenon and the
antiproteinuric effect of the drug was challenged by the obser-
vation that sodium salicylate, despite inhibiting PGE to compa-
rable extent, did not influence protein excretion. This argument
prompted the authors to consider it unlikely that the antipro-
teinuric effect of indomethacin is mediated by an inhibitory
effect on PG synthetic pathway. However, the urinary PGE is
primarily of medullary origin and therefore it might not be the
best marker for evaluating the effect of a drug purposed to
inhibit the synthesis of eicosanoids at cortical level.
The possibility that indomethacin favorably influences pro-
teinuria by inhibiting the synthesis of eicosanoids at cortical
level is consistent with recent findings. A relationship between
proteinuria and altered glomerular metabolism of AA has been
demonstrated in several experimental models of glomerular
damage. Using a model of nephrotoxic nephritis in rats Lianos,
Andres and Dunn [24] observed an increased synthesis of TxB2,
the stable breakdown product of TxA2, by isolated glomeruli,
which linearly correlated with the extent of proteinuria. No
correlation has been found between 6-keto-PGF1. and PGE2
urinary excretion and proteinuria, indicating that the cyclooxy-
genase metabolite which can play a contributory role in the
pathophysiology of proteinuria is likely to be Tx rather than
vasodilatory PGs. Our group has reported a significant increase
of both glomerular synthesis and urinary excretion of TxB2 in
rats with ADR nephrosis [25]. 6-keto-PGF1a and PGE2 urinary
excretion were not modified. These results suggest that AA
40—
30—
20—
10—
PHN
12th day
PHN
16th day
40—
30—
20—
10—
I
1.2-
1.0-
:
0.8-
0.6-
C)
E2 0.4-5)U)
0.2-
0-
Control PHN PHN+ PHN+
UK 38,485 indomethacin
Fig. 5. Effect of UK-38,485 (20 mg/kg i.p.) or indomethacin (6 mg/kg
on serum creatinine in rats with PHN at day 16 after anti-gp 330
serum injection. Results are expressed as mean SD.
*
PHN PHN+UK38,485
l2thday l6thday
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metabolism can be altered in glomerular disease, the most
consistent finding being a selective increase in the renal synthe-
sis of TxA2 that is reflected in an increased urinary excretion of
TxB2.
In PHN we have found that glomerular production of TxB2,
but not of 6-keto-PGF1,,, and PGE2 is increased in the
proteinuric phase of the disease. TxB2 urinary excretion pattern
paralleled the glomerular synthesis and was found to be normal
in the early phase of the disease before proteinuria develops but
significantly elevated 16 days after the administration of
heterologous serum when animals are heavily proteinuric. No
changes in 6-keto-PGFj and PGE2 urinary excretion have been
found in PHN in respect to normal rats. In our model indometh-
acm effectively inhibits urinary excretion of AA metabolites
and suppresses by greater than 70% the exaggerated urinary
excretion of TxB2. If indomethacin reduces proteinuria because
it inhibits renal TxA2 synthesis the same results could be
achieved by the use of a selective inhibitor of Tx-synthase.
However the administration of a selective Tx-synthase inhibitor
UK-38,485 at doses suppressing platelet TxA2 synthesis by
greater than 70% is unable to lower urinary protein excretion in
rats with PHN. The discrepancy between these findings and
those obtained with indomethacin could be explained at least in
part by the fact that in PHN UK-38,485 is less effective than
indomethacin in suppressing renal TxA2 synthesis. Actually at
variance with indomethacin, both doses of UK-38,485 em-
ployed were unable to inhibit urinary TxB2 excretion by more
than 44%. The finding that at the doses employed in the present
study UK-38,485 fully suppresses platelet TxA2 generation
suggests that this compound has differential effects on different
TxA2 producing cells. The relative resistance of renal Tx
synthase is a property which appears to be shared by all the
currently available, imidazole—like Tx-synthase inhibitors [26].
Our present data cannot rule out the possibility that other
actions of indomethacin [reviewed in 271, independently of the
cyclooxygenase inhibition, are responsible for the antiprotein-
uric effect of this drug. Despite the fact that the present data do
not implicate that TxA2 can cause proteinuria, if one considers
together the present results, those obtained by Lianos, Andres
and Dunn [24] and by Purkerson et al [28] it is tempting to
suggest an association between the antiproteinuric effect of the
different molecules used and their activity in suppressing TxB2
urinary excretion. It is possible that when the glomerular
membrane is already damaged by a disease process an increase
in TxA2 is one of the factors contributing to the loss of charge
or size selectivity properties. However we cannot exclude that
urinary excretion of TxB2 is only a marker of other system(s)
activation more directly responsible for amplifying the damage
of the filtering membrane. Similarly our present results do not
completely rule out the possibility that the increased urinary
excretion of TxB2 in PHN is a consequence of proteinuria. As
far as the cause of the increased renal Tx synthesis in PHN, it
has to be mentioned that PHN is associated with complement
activation, and that recent evidence has become available as to
indicate that complement activation may interfere with AA
metabolism leading to an increase in PG and Tx formation. In
particular, incubation of terminal complement components with
cultured glomerular epithelial cells induces a statistically signif-
icant release in PGE and TxB2 [29].
In conclusion, our present results together with those of
Kirschenbaum, Liebross and Serros [22] provide the experi-
mental basis for the clinical observation of Michielsen and
Lambert [I], and indicate that the antiproteinuric effect of
indomethacin can be observed without a concomitant reduction
in renal function. The efforts in finding more selective mole-
cules with antiproteinuric effect have to be pursued given the
consideration that the presence of proteinuria is associated with
a rapid progression in most glomerular diseases. In this context,
studies are needed to identify compounds more selective than
indomethacin to be used in experimental animals and humans
with nephrotic syndrome in order to obtain a reduction in
proteinuria.
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